id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-303959-e1654g5j	Vitiello, Antonio	COVID-19 Patients with Pulmonary Fibrotic Tissue: Clinical Pharmacological Rational of Antifibrotic Therapy	2020-08-27		.txt	text/plain	1917	89	38	In this direction, the use of a pharmacological approach to reduce or prevent fibrotic status, with antifibrotic agents such as pirfenidone, used with demonstrated clinical efficacy in idiopathic pulmonary fibrosis [4] can be a valuable aid in the prevention of serious or fatal complications from COVID-19 in patients with ongoing infection, or in those already healed with residual fibrotic lung lesions [5] . Although many patients who develop SARS-CoV-2 respiratory distress syndrome survive the acute phase of the Fig. 1 Antifibrotic therapy, pleiotropic effects of Pirfenidone disease, data have shown that some of them die from progressive pulmonary fibrosis [19] . Several reports suggest, however, that there are differences between IPF and COVID-19-induced pulmonary fibrosis, diversity in the rapid evolution of the fibrotic and inflammatory state, and a highly developed procoagulant effect in SARS-CoV-2 viral infection [22, 23] .	./cache/cord-303959-e1654g5j.txt	./txt/cord-303959-e1654g5j.txt